Invalidating a european patent
Earlier today, the Opposition Division of the European Patent Office (EPO) revoked Immunex's European Patent No. About Dupixent Dupixent comes in two doses (200 mg and 300 mg), each as a pre-filled syringe.
2,990,420 in its entirety because the claims were invalid for insufficiency of disclosure. Dupixent is intended for injection under the skin (subcutaneous injection) and is given every other week at different injection sites after an initial loading dose. as a treatment for adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable; and as add-on maintenance treatment for patients 12 years and older with moderate-to-severe asthma with an eosinophilic phenotype or with oral corticosteroid-dependent asthma.
In other words, circumstances require extensive and thorough search for locating prior art that can nullify the claims of the blocking patent.
Engage us on such complex evidence gathering tasks where we can assist you with extremely thorough & in-depth searches to locate invalidating prior art.
There are a variety of best practices for ensuring valid priority claims in Europe.
15, 2019 /PRNewswire/ -- Today the European Patent Office invalidated Immunex's European patent claiming antibodies that target human IL-4 receptors (IL-4R) Decision follows yesterday's ruling by the U. Patent & Trademark Office invalidating a similar Immunex patent claiming antibodies that target human IL-4R Regeneron Pharmaceuticals, Inc. and European patent offices this week, which invalidate Immunex's functional patent claims to antibodies that target human IL-4 receptors," said Joseph La Rosa, Executive Vice President, General Counsel and Secretary, Regeneron. Dupixent is a targeted biologic therapy that binds to IL-4R and inhibits signaling of IL-4 and IL-13, two key proteins that play a central role in Type 2 inflammation that underlies a number of allergic diseases, including atopic dermatitis and asthma.These potential uses are investigational and the safety and efficacy have not been evaluated by any regulatory authority. INDICATIONS DUPIXENT is a prescription medicine used: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.Dupilumab and REGN3500 were discovered using Regeneron's proprietary Veloc Immune technology that yields optimized fully human antibodies, and are being jointly developed by Regeneron and Sanofi under a global collaboration agreement. If you are taking asthma medicines, do not change or stop your asthma medicine without talking to your healthcare provider.This follows a decision yesterday by the Patent Trial and Appeal Board (PTAB) of the U. Patent & Trademark Office (USPTO) to invalidate all 17 claims of Immunex's U. It can be given in a clinic or, for convenience, at home by self-administration after training by a healthcare professional. In the EU, Dupixent is approved for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.Dupilumab Development Program Regeneron, in collaboration with Sanofi, is also studying dupilumab in a broad range of clinical development programs for diseases driven by allergic and other Type 2 inflammation, including chronic rhinosinusitis with nasal polyps (Phase 3 completed), adolescent (12 to 17 years of age) atopic dermatitis (Phase 3 completed), pediatric (6 to 11 years of age) atopic dermatitis (Phase 3), pediatric (6 months to 5 years of age) atopic dermatitis (Phase 2/3), pediatric (6 to 11 years of age) asthma (Phase 3), eosinophilic esophagitis (Phase 3) and food and environment allergies (Phase 2).